ID Week – New Intestinal Necrosis Data
Dr. Parvathi Kumar, ReAlta’s Associate Director of Early Clinical Development, will be presenting data on the novel peptide inhibitor RLS-0071 at ID Week 2021 (September 29 – October 3rd). IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Dr. Kumar is the presenting author of RLS-0071 Improves Survival in Rat Model of Intestinal Necrosis in the Microbial Pathogens session.
RLS-0071 is a dual targeting, anti-inflammatory peptide that inhibits complement and inflammatory processes such as neutrophil activation and NETosis. RLS-0071 was demonstrated to increase survival and reduce inflammation in a pre-clinical model of intestinal necrosis demonstrating its potential utility as a clinical therapeutic for various disease processes associated with intestinal necrosis such as intestinal infarction (i.e. ischemia reperfusion injury of intestinal tissue). At this conference, Dr. Kumar will discuss how the RLS-0071-treated animals demonstrated a 1.5-fold increase in survival compared to untreated animals. This data demonstrates that immunomodulation of the complement system and neutrophil effectors by RLS-0071 may have utility as a therapeutic for the treatment of intestinal necrosis in humans.
More information about IDWeek, including virtual meeting and other attendees, can be found at the link here.